

## San Antonio Breast Cancer Symposium

Henry B. Gonzalez Convention Centre

December 6-10, 2022

### Abstracts<sup>1</sup>

**CCTG MAC.15/SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast**

**Time:** December 6, 2022; 2:00-2:15 PM

**Type:** Oral

**Session:** General Session 1

**Abstract:** *Race and clinical outcomes in the RxPONDER Trial (SWOG S1007)*

**Abstract #:** GS1-01

**Authors:** Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SK, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Puztai L, Hortobagyi GN, Kalinsky K

**Page #:** 22 of the online December 7 AM (Tuesday) program

---

**CCTG MAC.15/SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer**

**Time:** December 6, 2022; 2:45-3:00 PM

**Type:** Oral

**Session:** General Session 1

**Abstract:** *Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status*

**Abstract #:** GS1-04

**Authors:** Kang I, Forschmiedt JK, Loch MM, Barlow WE, Lew DL, Gralow JR, Meric-Bernstam F, Albain KS, Hayer DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Miao J, Tripathy D, Puztai L, Hortobagyi GN, Kalinsky K, Henry NL.

**Page #:** 23 of the online December 7 AM (Tuesday) program

---

<sup>1</sup>Online abstracts are available on the SABCS website beginning March 2023. They are also viewable by using this link <https://www.sabcs.org/> and clicking on the links to the daily program. Page numbers are provided for easier reference. These abstracts will also be published in the symposium's abstract book, a special supplement to the AACR journal **Cancer Research** which is available in March 2023.

**CCTG MAC.15/SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer.**

**Time:** December 7, 2022; 9:45-11:00 AM

**Type:** Poster

**Session:** Special Session

**Abstract:** *HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score < / 25 randomized to endocrine therapy +/- chemotherapy: results from SWOG S1007 (RxPONDER)*

**Abstract #:** HER2-19

**Authors:** Spring LM, Barlow WE, Bardia A, Sharma P, Puzstai L, Hortobagyi GN, Kalinsky K.

**Page #:** 759 of the online December 7 AM (Wednesday) program

---

**CCTG MAC.15/SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast**

**Time:** December 9, 2022; 8:00 – 8:15 AM

**Type:** Poster

**Session:** Poster Session 6; Detection and Diagnosis: Diagnostic Pathology

**Abstract:** *Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status*

**Abstract #:** P6-05-06

**Authors:** Loch MM, Forschmiedt JK, Kang IM, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Barlow W, Tripathy D, Puzstai L, Hortobagyi GN, Kalinsky K.

**Page #:** 236 of the online December 9 (Friday) program

---

**CCTG MAC.12/ECOG PACCT-1 – Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial**

**Time:** December 6, 2022; 3:00 – 3:15 PM

**Type:** Oral

**Session:** General Session 1

**Abstract:** *Trial assigning individualized options for treatment (TAILORx): An Update Including 12-Year Event Rates*

**Abstract #:** GS1-05

**Authors:** Sparano J, Gray RJ, Makower D, Albain KS, Hayes DF, Geyer C, Dees E, Goetz MP, Olson JA, Lively TG, Badve S, Saphner T, Wagner LI, Whelan T, Kaklamani V, Sledge G.

**Page #:** 29 of the online December 6 (Tuesday) program

---

## Not Trial-Specific

**Time:** December 6, 2022; 5:00 – 6:15 PM  
**Type:** Poster  
**Session:** Poster Session 1 – Adjuvant Endocrine Therapy  
**Abstract:** *Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis*  
**Abstract #:** P1-02-01  
**Authors:** Janni W, Untch M, Harbeck N, Gilgorov J, Jacot W, Chia SK, Boileau JF, Haftchenary S, Gupta R, Mishra N, Pathak P, Curigliano G  
**Page #:** 192 of the online December 6 (Tuesday) program

---

## CCTG MA.9 / SWOG 8814: Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors

**Time:** December 7, 2021; 7:00 – 8:15 PM  
**Type:** Poster  
**Session:** Poster Session 2 – Prognostic & Predictive Factors: Prognosis-Biomarkers of Natural History-Prog Factors-Clin Testing & Val  
**Abstract:** *Computer analysis of nuclear morphology with multiple instance learning Predicts overall survival for node positive breast cancer patients from SWOG S8814: A blinded validation study*  
**Abstract #:** P2-11-11  
**Authors:** Shao D, Barlow WE, Li H, Lu C, Albain KS, Rae J, Hayes, DF, Godwin AK, Thompson AM, Madabhushi A, Puztai L.  
**Page #:** 193 of the online December 7 PM (Wednesday) program

---

## CCTG MA.9 / SWOG 8814: Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors

**Time:** December 7, 2021; 7:00 – 8:15 PM  
**Type:** Poster  
**Session:** Poster Session 2 – Prognostic & Predictive Factors: Prognosis-Biomarkers of Natural History-Prog Factors-Clin Testing & Val  
**Abstract:** *Computerized measurements of nuclear morphology features, mitosis rate, and tubule formation from H&E images predicts disease-free survival in patients with HR+ & LN+ invasive breast cancer from SWOG S8814*  
**Abstract #:** P2-11-16  
**Authors:** Chen Y, Barlow WE, Li H, Lu C, Janowczyk A, Corredor G, Ganesan S, Feldman M, Fu P, Gilmore H, Albain KSH, Puztai L, Rae J, Hayes D, Godwin AK, Thompson AM, Madabhushi A.  
**Page #:** 209 of the online December 7 PM (Wednesday) program

---

**CCTG IND.236: A Phase IB and Open Label Phase II Study of CFI-402257 in Combination with Weekly Paclitaxel in Patients with Advanced/Metastatic HER2-Negative Breast Cancer**

**Time:** December 7, 2021; 5:00 – 6:15 PM

**Type:** Poster

**Session:** Poster Session 3 – Treatment: Therapeutic Strategies – New Drugs and Treatment Strategies

**Abstract:** *A Phase 1b trial of combined CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC)*

**Abstract #:** P3-07-10

**Authors:** Bedard P, Mates M, Hilton J, Lavoie N, Awan A, Srikanthan A, Cescon DW, Gelmon K, Robinson A, Dummond-Ivars N, Li I, Rastgou L, Edwards J, Hagerman L, Zhang S, Bray, M, Seymour L, Rushton M, Gaudreau PO.

**Page #:** 565 of the online December 7 PM (Wednesday) program

---

**CCTG IND.237: A Phase II Study of CFI-400945 in Patients with Advanced/Metastatic Breast Cancer**

**Time:** December 7, 2021; 5:00 – 6:15 PM

**Type:** Poster

**Session:** Poster Session 3 – Treatment: Therapeutic Strategies – New Drugs and Treatment Strategies

**Abstract:** *A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND.237*

**Abstract #:** P3-07-14

**Authors:** Cescon DW, Hilton J, Bedard P, Blachette P, Pezo RC, Bashir A, Kumar V, Ng TL, Awan A, Lott A, Raphael JA, Hagerman L, Bray M, Muyot L, Antras JF, Seymour L, Tu D, Gaudreau PO, Rushton M.

**Page #:** 582 of the online December 7 PM (Wednesday) program

---

**CCTG IND.239: A Phase II Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer (TNBC)**

**Time:** December 7, 2021; 5:00 – 6:15 PM

**Type:** Poster

**Session:** Poster Session 3 – Treatment: Therapeutic Strategies – New Drugs and Treatment Strategies

**Abstract:** *CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC)*

**Abstract #:** P3-07-18

**Authors:** Hilton J, Cescon DW, Robinson A, Dhesy-Thind S, Taylor S, Ng TL, Rushton M, Savard MF, Muyot L, Reeves MC, Hagerman L, Lui H, Bray M, Tu D, Seymour L, Gaudreau PO.

**Page #:** 593 of the online December 7 PM (Wednesday) program

---

**CCTG MA.20: A Phase III Study of Regional Radiation Therapy in Early Breast Cancer**

**Time:** December 8, 2021; 7:00 – 8:15 AM

**Type:** Poster

**Session:** Poster Session 4 – Prognostic and Predictive Factors: Biomarkers Predicting Tx Response: Predictive Biomarkers - Other

**Abstract:** *Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional radiotherapy trial*

**Abstract #:** P4-02-16

**Authors:** Riaz N, Chen B, Bane A, Gao D, Stovgaard E, Kos Z, Leung S, Shenasa E, Parulekar W, Chambers S, Nielsen T, Whelan TJ.

**Page #:** 187 of the online December 8 AM (Thursday) program

---

**CCTG MA.40: A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)**

**Time:** December 8, 2021; 5:00 – 6:15 PM

**Type:** Poster

**Session:** Ongoing Trials Poster Session 3 – Targeting PI3K/mTOR

**Abstract:** *CCTG MA40: Double-blind placebo controlled phase III trial of fulvestrant and ipatasertib for advanced her-2 negative and estrogen receptor positive (er+) breast cancer post first line cdk 4/6 and aromatase inhibitor therapy (finer)*

**Abstract #:** OT3-26-01

**Authors:** Chia SK, Cescon DW, Redfern AD, Rodin D, Simmons C, Ayoub JP, Ibrahim H, Rayson D, Rushton-Marovac M, Hay T, Gallinaro L, Chen B, Parulekar W.

**Page #:** 203 of the online December 8 PM (Thursday) program

---

**CCTG MA.38: Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer**

**Time:** December 8, 2021; 5:00 – 6:15 PM

**Type:** Poster

**Session:** Poster Session 5 – Prognostic and Predictive: Biomarkers Predicting Tx Response: For Targeted Therapies

**Abstract:** *Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial*

**Abstract #:** P5-02-27

**Authors:** McCartney A, Biagioni C, Chen B, Shepherd L, Gelmon K, Joy AA, Parulekar W, Bergqvist M, Migliaccio I, Leo A, Benelli M, Risi E, Moretti E, Luca L, Biganzoli L, Malorni L.

**Page #:** 336 of the online December 8 PM (Thursday) program

**Link:** TBC

---